With use of SEREX, serum AAbs to the glycoprotein Fbln-1 were identified in 15/20 (75%) breast carcinoma patients compared to 4/20 (25%) healthy controls (P < .0006) [42, 110]. Here, FBLN1 is linked to breast carcinoma.